Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Brentuximab vedotin→

Brentuximab vedotin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
914088-09-8
FDA UNII
7XL5ISS668
PubChem Substance Record
SID 481101546
Approximate molecular weight
Approximately 153 kDa
Drug class
CD30-directed antibody–drug conjugate (brentuximab vedotin)
Mechanism of action
Brentuximab vedotin binds CD30 on target cells and is internalised. Lysosomal proteolysis releases monomethyl auristatin E (MMAE), which binds tubulin, disrupts microtubules, induces cell-cycle arrest and promotes apoptosis.
Indications / reported uses
  • EMA-authorised indications include selected CD30-positive Hodgkin lymphoma, systemic anaplastic large-cell lymphoma and cutaneous T-cell lymphoma settings; consult current product information for exact lines and combinations

Sources: EMA EPAR — Adcetris · EMA product information · NCI Drug Dictionary

Identification sources: The FDA ADCETRIS prescribing information reports an approximate molecular weight of 153 kDa and approximately four MMAE molecules per antibody. Because the drug-to-antibody ratio varies, the conjugate has no single exact molecular formula or molecular weight.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Brentuximab vedotin Environmental Risk Assessment (ERA) (the Brentuximab vedotin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.